Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LSA3-FL
- Development stage
- Unknown
- Lead developer
- Vac4All
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
LSA3-FL is a first-generation recombinant protein vaccine developed by Vac4All targeting the liver stage (pre-erythrocytic stage) of *Plasmodium falciparum* malaria. The vaccine is based on the full-length Liver Stage Antigen 3 (LSA3) protein and is part of Vac4All's STOPMAL vaccine program, which aims to block sporozoite and liver stages of the malaria parasite following a mosquito bite. In Phase 1 clinical trials, LSA3-FL demonstrated safety and immunogenicity in humans, and proof-of-concept studies in chimpanzees showed protection against *P. falciparum* sporozoite challenges up to one year after immunization. However, the first-generation prototype induced immune responses that were found to be restricted by the presence of regulatory regions on the vaccine construct, leading Vac4All to design second-generation candidates with these regions removed to enhance immune response magnitude and duration.
- Other names
- LSA3-FL-Vac4All-LSA3-protein vaccineLSA-3-FL-Vac4All-LSA3-protein vaccineLSA 3-FL-Vac4All-LSA3-protein vaccinefull-length LSA3 vaccine
02
Targets
LSA-3 (Plasmodium falciparum liver-stage antigen 3)
Beyond the preview
Go deeper on LSA3-FL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LSA3-FL.